Xu J - Search Results

1

ELF3 promotes epithelial-mesenchymal transition by protecting ZEB1 from miR-141-3p-mediated silencing in hepatocellular carcinoma.

Zheng L, Xu M, Xu J, Wu K, Fang Q, Liang Y, Zhou S, Cen D, Ji L, Han W, Cai X. Zheng L, et al. Among authors: xu m, xu j. Cell Death Dis. 2018 Mar 9;9(3):387. doi: 10.1038/s41419-018-0399-y. Cell Death Dis. 2018. PMID: 29523781 Free PMC article.

2

Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.

Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C. Shi L, et al. Among authors: xu j. Cancer Lett. 2016 Apr 1;373(1):45-56. doi: 10.1016/j.canlet.2016.01.017. Epub 2016 Jan 19. Cancer Lett. 2016. PMID: 26805759 Free PMC article.

3

Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.

Shi L, Lin H, Li G, Jin RA, Xu J, Sun Y, Ma WL, Yeh S, Cai X, Chang C. Shi L, et al. Among authors: xu j. Mol Cancer Ther. 2016 Apr;15(4):731-742. doi: 10.1158/1535-7163.MCT-15-0706. Epub 2016 Mar 3. Mol Cancer Ther. 2016. PMID: 26939703 Free PMC article.

4

Sorafenib with ASC-J9^® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.

Xu J, Lin H, Li G, Sun Y, Shi L, Ma WL, Chen J, Cai X, Chang C. Xu J, et al. Int J Cancer. 2017 Feb 1;140(3):705-717. doi: 10.1002/ijc.30446. Epub 2016 Nov 9. Int J Cancer. 2017. PMID: 27668844 Free PMC article.

5

The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.

Xu J, Lin H, Li G, Sun Y, Chen J, Shi L, Cai X, Chang C. Xu J, et al. EBioMedicine. 2016 Oct;12:55-67. doi: 10.1016/j.ebiom.2016.07.013. Epub 2016 Jul 14. EBioMedicine. 2016. PMID: 27688096 Free PMC article.

6

Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.

Xu J, Zheng L, Chen J, Sun Y, Lin H, Jin RA, Tang M, Liang X, Cai X. Xu J, et al. Cell Death Dis. 2017 Oct 12;8(10):e3095. doi: 10.1038/cddis.2017.411. Cell Death Dis. 2017. PMID: 29022906 Free PMC article.

7

Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.

Liang Y, Chen J, Yu Q, Ji T, Zhang B, Xu J, Dai Y, Xie Y, Lin H, Liang X, Cai X. Liang Y, et al. Among authors: xu j. Cancer Med. 2017 Dec;6(12):2787-2795. doi: 10.1002/cam4.1228. Epub 2017 Oct 13. Cancer Med. 2017. PMID: 29030911 Free PMC article.

8

Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.

Wang M, Sun Y, Xu J, Lu J, Wang K, Yang DR, Yang G, Li G, Chang C. Wang M, et al. Among authors: xu j. Int J Cancer. 2018 Jul 1;143(1):100-112. doi: 10.1002/ijc.31289. Epub 2018 Apr 2. Int J Cancer. 2018. PMID: 29396852 Free PMC article.

9

TR₄ nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression.

Jin R, Lin H, Li G, Xu J, Shi L, Chang C, Cai X. Jin R, et al. Among authors: xu j. Cell Death Dis. 2018 Feb 15;9(3):283. doi: 10.1038/s41419-018-0287-5. Cell Death Dis. 2018. PMID: 29449527 Free PMC article.

10

Clinicopathological features and survival for gallbladder NEN: a population-based study.

Cen D, Liu H, Wan Z, Lin Z, Wang Y, Xu J, Liang Y. Cen D, et al. Among authors: xu j. Endocr Connect. 2019 Sep;8(9):1273-1281. doi: 10.1530/EC-19-0124. Endocr Connect. 2019. PMID: 31398710 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67,534 results

Search Page

Filters